Myriad Genetics (MYGN) Tops Q3 EPS by 3c, Offers Q4 & FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Leerink Partners Remains Sidelined on Myriad Genetics (MYGN) - PT to $41
May 4, 2016 7:44 AM EDTLeerink Partners maintained a Market Perform rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $41.00 (from $44.00), following the company's 3Q earnings report. MYGN reported revenue of $190.5M, beating expectations of $185M by ~3%. Management guided F4Q revenue in the... More
Myriad Genetics (MYGN) Beat But Not By Enough, Mizuho Says; PT to $34
May 4, 2016 6:55 AM EDTMizuho analyst, Eric Criscuolo, cut his price target on Myriad Genetics (NASDAQ: MYGN) to $34 from $42 and reduced the projected PE multiple to 20x from 22x. No change to Neutral rating.
Myriad beat consensus top line estimates by $6mm and EPS by $0.03.... More
